The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8771-8779

  Song, Hyun Jin ^a   Lee, Eui Kyung ^a   Lee, Jun Ah ^b   Kim, Hye Lin ^a   Jang, Kyoung Won ^a  

^a Sungkyunkwan University   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Decision analysis; Markov model; Mifamurtide; Osteosarcoma; Quality adjusted life years

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; MIFAMURTIDE; ANTINEOPLASTIC AGENT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; PHOSPHATIDYLETHANOLAMINE;

ADD ON THERAPY; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; EVENT FREE SURVIVAL; HEALTH SURVEY; HIDDEN MARKOV MODEL; HUMAN; INDUCTION CHEMOTHERAPY; LIFE EXPECTANCY; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; COHORT ANALYSIS; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PROBABILITY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MARKOV CHAINS; MONTE CARLO METHOD; OSTEOSARCOMA; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHATIDYLETHANOLAMINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 84919873610     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2139-y     Document Type: Article

References (21)

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognosticfactors in high-gradeosteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.
2. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyltripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11.
3. Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van Glabbeke M, Grimer RJ, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011;47(6):895–902.
4. National Cancer Information Center. http://www.cancer.go.kr/mbs/cancer/ [Assessed 21 November 2013].
5. Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2009.
6. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–65.
7. Lee JA, Kim MS, Kim DH, Lim JS, Park KD, Song WS, et al. Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer. 2009;52:340–5.
8. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyltripeptide to chemotherapy improves overall survival-a report from the Children’s Oncology Group. J Clin Oncol. 2008;26(4):633–8.
9. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–68.
10. Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifarmurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12(2):285–92.
11. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. New York: Oxford University Press Inc.; 2005.
12. Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. New York: Oxford University press Inc.; 2006.
13. Rascati KL. Essentials of pharmacoeconomics. Lippincott Williams & Wilkins, a Wolters Kluwer business. 2009.
14. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. New York: Oxford University Press Inc.; 2011.
15. Johal S, Ralston S, Knight C. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. Value Health. 2013;16(8):1123–32.
16. The guideline of Pharmacoeconomics in South Korea. Health Insurance Review andAssessment. 2011.
17. Yu G, Sung G. Diagnosis and treatment of osteosarcoma. ChosunIlbo, Samsung Medical Center. 2006.
18. Complete Life Table 2010. Korean Statistical Office. 2010. Available at: http://kostat.go.kr[Accessed 21 November 2013].
19. Song HJ, Lee JA, Lee EK. Dealing with negative utility scores for health states of worse than death (Working paper).
20. Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, et al. Mifamurtide in metastatic and recurrrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamics, and Safety assessments. Pediatr Blood Cancer. 2014;61(2):238–44.
21. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and the Valueing Health Benefits for Economic Evaluation. New York: Oxford University Press Inc.; 2007.